TACR1 and neoplasm: Many studies have shown that the SP/NK-1R system is involved in cancer, that the NK-1R is a crucial target for the treatment of cancer (tumor cells overexpress the NK-1R) and that NK-1R antagonists are potential broad-spectrum antitumor drugs [for a review, see 13].